Agomab Therapeutics has secured $89 million in Series D financing to advance clinical development of its leading drug candidates with new participation from investors Sanofi and Invus.
Target Company Overview
Agomab Therapeutics NV is a biopharmaceutical company focused on developing innovative therapies for severe diseases, particularly in the fields of gastroenterology and respiratory medicine. The company is currently advancing its clinical pipeline, which includes novel treatments targeting conditions such as fibrostenosing Crohn’s disease, idiopathic pulmonary fibrosis, and liver cirrhosis.
Recently, Agomab announced a significant Series D financing round to fund the clinical development of its lead candidates. This funding will enable the company to progress its clinical trials and further validate the efficacy of its therapies in addressing unmet medical needs.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Belgium
Belgium has emerged as a hub for biopharmaceutical research and development in Europe, supported by strong academic institutions and a favorable regulatory environment. The count
Similar Deals
Cochlear, Resmed, Nyxoah’s Chairman and Management → Nyxoah SA
2025
Fidelity Management & Research Company → Agomab Therapeutics NV
2023
Sanofi, Invus
invested in
Agomab Therapeutics NV
in 2024
in a Other deal
Disclosed details
Transaction Size: $89M